Elecsys® total PSA, a quantitative in vitro diagnostic test for determination of total (free + complexed) prostate specific antigen (tPSA) in human serum and plasma.
Prostate cancer is the second most common cancer in men and the leading death cause from cancer in men.1 Early detection ensures timely management and treatment before prostate cancer can cause potentially fatal conditions.2
Screening approaches have reduced prostate cancer mortality in the USA and in Europe.3,4,5 The most widely used screening tests for prostate cancer are digital rectal examination (DRE) in combination with serum total PSA.6
Guidelines recommend PSA screening in men at higher risk of developing prostate cancer, based on risk factors including age, family history and race.7,8,9
Total PSA can also be used to do active surveillance, assess therapy response and for post-treatment follow up.10
The National Comprehensive Cancer Network (NCCN) and the European Association of Urology suggest testing every 2–4 years when PSA >1 ng/mL, with repeat testing up to 8 years later when PSA levels are <1 ng/mL.8,9